Hsin-Yu Chen1, Peder E.Z. Larson1,2, Robert A. Bok2, Cornelius von Morze2, Renuka Sriram2, Romelyn Delos Santos2, Justin Delos Santos2, Jeremy W. Gordon2, John Kurhanewicz1,2, and Daniel B. Vigneron1,2
1Graduate Program in Bioengineering, UCSF and UC Berkeley, University of California, San Francisco, San Francisco, CA, United States, 2Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, United States
An unmet
clinical need facing the management of prostate cancer is an accurate method
for distinguishing aggressive prostate cancer from indolent disease. The project
investigated the use of hyperpolarized (HP) 13C 3D CS-EPSI imaging
of co-polarized 13C-urea + 13C-pyruvate to provide this
distinction by simultaneously measuring metabolism and perfusion. Significantly
higher pyruvate-to-lactate conversion rates, kPL, (P<0.00001) and
significantly (P<0.004) lower urea perfusion were detected in high-grade
tumors compared to low-grade tumor. Lymph-node metastases demonstrated high
metabolic conversion (P>0.8) and urea perfusion not significantly (P>0.4)
different than high-grade primary tumor.
